[{"address1": "Carl Jacobsens Vej 30", "address2": "Valby", "city": "Copenhagen", "zip": "2500", "country": "Denmark", "phone": "45 70 20 27 28", "website": "https://www.genmab.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, Anthropic PBC, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.", "fullTimeEmployees": 2681, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jan G.J. van de Winkel Ph.D.", "age": 64, "title": "Co-Founder, President & CEO", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 3217162, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anthony  Pagano CPA", "age": 47, "title": "Executive VP & CFO", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 1182780, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rayne  Waller", "age": 57, "title": "Executive VP & Chief Technical Operations Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 801136, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Cozic", "age": 46, "title": "Executive VP & Chief People Officer", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 867372, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Martine J. van Vugt Ph.D.", "age": 54, "title": "Executive VP & Chief Strategy Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 820061, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Martin  Schultz", "age": 50, "title": "Senior Director, Head of Development Business Partnership & Strategy and Director", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 220786, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Judith V. Klimovsky M.D.", "age": 67, "title": "Executive VP & Chief Development Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 1340484, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tahamtan  Ahmadi M.D., Ph.D.", "age": 53, "title": "Executive VP, Chief Medical Officer & Head of Experimental Medicines", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 1245862, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mijke  Zachariasse Ph.D.", "age": 52, "title": "VP, Head of Antibody Research Materials & Director", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 252326, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Takahiro  Hamatani", "age": 50, "title": "Senior Director of Finance Japan & Non-Independent Director", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 220786, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://ir.genmab.com/index.cfm", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 30.97, "open": 30.94, "dayLow": 30.75, "dayHigh": 31.31, "regularMarketPreviousClose": 30.97, "regularMarketOpen": 30.94, "regularMarketDayLow": 30.75, "regularMarketDayHigh": 31.31, "payoutRatio": 0.0, "beta": 0.795, "trailingPE": 13.552631, "forwardPE": 20.76906, "volume": 1758139, "regularMarketVolume": 1758139, "averageVolume": 1622516, "averageVolume10days": 1442770, "averageDailyVolume10Day": 1442770, "bid": 30.86, "ask": 30.98, "bidSize": 2, "askSize": 1, "marketCap": 19034185728, "fiftyTwoWeekLow": 17.235, "fiftyTwoWeekHigh": 35.43, "allTimeHigh": 103.19, "allTimeLow": 0.654, "priceToSalesTrailing12Months": 4.9495106, "fiftyDayAverage": 32.4998, "twoHundredDayAverage": 26.83675, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -1366572032, "profitMargins": 0.41169998, "floatShares": 60849374, "sharesOutstanding": 615993070, "sharesShort": 9908231, "sharesShortPriorMonth": 11499724, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.0161, "heldPercentInsiders": 0.0, "heldPercentInstitutions": 0.106680006, "shortRatio": 6.11, "shortPercentOfFloat": 0.0163, "impliedSharesOutstanding": 615993070, "bookValue": 93.41, "priceToBook": 0.33079967, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "earningsQuarterlyGrowth": 1.016, "netIncomeToCommon": 1583268864, "trailingEps": 2.28, "forwardEps": 1.48779, "lastSplitFactor": "5:1", "lastSplitDate": 1525132800, "enterpriseToRevenue": -0.355, "enterpriseToEbitda": -0.928, "52WeekChange": 0.6532905, "SandP52WeekChange": 0.14272952, "quoteType": "EQUITY", "currentPrice": 30.9, "targetHighPrice": 48.0, "targetLowPrice": 25.0, "targetMeanPrice": 37.92857, "targetMedianPrice": 38.5, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 3411000064, "totalCashPerShare": 55.403, "ebitda": 1472946816, "totalDebt": 142000000, "quickRatio": 6.015, "currentRatio": 6.034, "totalRevenue": 3845670144, "debtToEquity": 2.469, "revenuePerShare": 6.1295, "returnOnAssets": 0.13377, "returnOnEquity": 0.29413, "grossProfits": 3628929536, "freeCashflow": 955981952, "operatingCashflow": 1368800768, "earningsGrowth": 1.076, "revenueGrowth": 0.174, "grossMargins": 0.94364, "ebitdaMargins": 0.38301, "operatingMargins": 0.44912, "financialCurrency": "USD", "symbol": "GMAB", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1770425819, "regularMarketTime": 1770411601, "exchange": "NMS", "messageBoardId": "finmb_665704", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -0.226024, "regularMarketPrice": 30.9, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1243863000000, "postMarketChangePercent": -0.32362583, "postMarketPrice": 30.8, "postMarketChange": -0.10000038, "regularMarketChange": -0.0699997, "regularMarketDayRange": "30.75 - 31.31", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1622516, "fiftyTwoWeekLowChange": 13.664999, "fiftyTwoWeekLowChangePercent": 0.79286325, "fiftyTwoWeekRange": "17.235 - 35.43", "fiftyTwoWeekHighChange": -4.5300007, "fiftyTwoWeekHighChangePercent": -0.12785776, "fiftyTwoWeekChangePercent": 65.32905, "earningsTimestamp": 1771362000, "earningsTimestampStart": 1771362000, "earningsTimestampEnd": 1771362000, "earningsCallTimestampStart": 1770915600, "earningsCallTimestampEnd": 1770915600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 2.28, "epsForward": 1.48779, "epsCurrentYear": 1.9118, "shortName": "Genmab A/S", "longName": "Genmab A/S", "marketState": "CLOSED", "priceEpsCurrentYear": 16.162779, "fiftyDayAverageChange": -1.599802, "fiftyDayAverageChangePercent": -0.049224976, "twoHundredDayAverageChange": 4.0632496, "twoHundredDayAverageChangePercent": 0.15140617, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "trailingPegRatio": 0.6004, "__fetch_time": "2026-02-07"}]